We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





Study Finds Immunity to Coronavirus May Last Only Six Months with Reinfection Possible

By HospiMedica International staff writers
Posted on 30 May 2020
Print article
Illustration
Illustration
A study by the University of Amsterdam (Amsterdam, the Netherlands) has found that immunity to human coronaviruses may last for only six months with a possibility of reinfection.

These findings have raised doubts over the effectiveness of "immunity passports" to be issued by some governments to COVID-19 survivors based on the assumption that they cannot be reinfected and would contribute to reviving the economy.

In the study, the researchers monitored 10 men aged over 35 years to determine their antibody levels after they had been infected with any of the four seasonal human coronaviruses. The men, then aged 27 to 40-years old, were then tested at an interval of either three or six months. The researchers discovered an "alarmingly short duration of protective immunity to coronaviruses" and observed "frequent reinfections at 12 months post-infection and substantial reduction in antibody levels as soon as 6 months post-infection."

According to the researchers, the four strains of human coronaviruses are "biologically dissimilar" and “have little in common, apart from causing the common cold, although “they all seem to induce a short-lasting immunity with rapid loss of antibodies. This may well be a general denominator for human coronaviruses. If SARS-CoV-2 will behave like a seasonal coronavirus in the future, a similar pattern may be expected.” The researchers warned that "as protective immunity may be lost by 6 months post-infection, the prospect of reaching functional herd immunity by natural infection seems very unlikely.”

Related Links:
University of Amsterdam

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Vital Signs Monitor
Aurus 10

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.